Eli Lilly’s Stomach-Cancer Drug Improves Survival
This article is for subscribers only.
Eli Lilly & Co.’s experimental stomach cancer drug helped patients with advanced disease live longer, a study found. The shares rose.
The most common side effects for the medicine, called ramucirumab, were high blood pressure, diarrhea and headache, the Indianapolis-based company said in a statement today. The drug was tested in patients with gastric cancer that has spread to other parts of the body.